БЕМОН Мария Глория (FR),ХЕРДИНИУС Стефан Рикард (BE),ПИККИО Гастон Рафаэл (US),ПОЛО Рамон (US),КАУФФМАН Роберт С. (US),АДИВИДЖАЯ Бамбанг С. (US),ГАРГ Варун (US)
申请号：
RU2010153688/15
公开号：
RU2010153688A
申请日:
2009.06.10
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A method of treating HCV infected patients, comprising administering a combination of telaprevir with pegylated interferon, the treatment comprising:! (a) the introductory phase of administering to the patient pegylated interferon and ribavirin, and! (b) the treatment phase with the introduction of a combination of telaprevir, pegylated interferon and ribavirin to the patient,! however, there is no time delay between the introductory phase and the treatment phase. ! 2. The method according to claim 1, where the treatment further includes! (c) the subsequent phase of treatment with the introduction of the patient pegylated interferon and ribavirin. ! 3. The method according to claim 2, where there is no time delay between the treatment phase and the subsequent treatment phase. ! 4. The method according to any one of claims 1 to 3, where HCV infected patients are infected with HCV 1 genotype. ! 5. The method according to any one of claims 1 to 3, where the HCV-infected patient is re-ill or not having a response to treatment. ! 6. The method according to any one of claims 1 to 3, wherein the HCV-infected patient has not previously been treated. ! 7. The method according to any one of claims 1 to 3, where the introductory phase takes from two to 6 weeks. ! 8. The method according to any one of claims 1 to 3, where the introductory phase takes 4 weeks. ! 9. The method according to any one of claims 1 to 3, where the treatment phase takes from eight to sixteen weeks. ! 10. The method according to any one of claims 1 to 3, where the treatment phase takes 12 weeks. ! 11. The method according to claim 2 or 3, where the subsequent phase of treatment takes from 26 to 36 weeks. ! 12. The method according to claim 2 or 3, where the subsequent phase of treatment takes 32 weeks. ! 13. The method according to any one of claims 1 to 3, where during the treatment phase, telaprevir is administered in an amount equal to 750 mg, every 8 hours! 14. The combination of telaprevir with p
